Association between altered brain morphology and elevated peripheral endothelial markers - Implications for psychotic disorders

Schizophrenia Research

Volumn 161, Issue 2-3, 2015, Pages 222-228

  Dieset, Ingrid ^a   Haukvik, Unn Kristin ^a,b   Melle, Ingrid ^a   Røssberg, Jan Ivar ^a   Ueland, Thor ^c   Hope, Sigrun ^a   Dale, Anders M ^e   Djurovic, Srdjan ^a,d   Aukrust, Pål ^c   Agartz, Ingrid ^a,b   Andreassen, Ole A ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b DIAKONHJEMMET HOSPITAL   (Norway)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

^d ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Basal ganglia; Brain morphology; Endothelial markers; Inflammation

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; CD40 LIGAND; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 6; NEUROLEPTIC AGENT; OSTEOPROTEGERIN; TUMOR NECROSIS FACTOR RECEPTOR 1; VON WILLEBRAND FACTOR; CYTOKINE; PLASMA PROTEIN;

ADULT; AFFECTIVE PSYCHOSIS; ARTICLE; BASAL GANGLION; BRAIN DISEASE; BRAIN LEVEL; BRAIN SIZE; CONTROLLED STUDY; DISEASE ASSOCIATION; ENDOTHELIAL DYSFUNCTION; FEMALE; GLOBUS PALLIDUS; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROANATOMY; NUCLEAR MAGNETIC RESONANCE IMAGING; PROTEIN BLOOD LEVEL; PSYCHOSIS; SCHIZOPHRENIA; STRUCTURAL BRAIN ABNORMALITY; BLOOD; BRAIN; IMAGE PROCESSING; METABOLISM; MIDDLE AGED; PATHOLOGY; PSYCHOLOGICAL RATING SCALE; STATISTICAL MODEL; YOUNG ADULT;

ADULT; BLOOD PROTEINS; BRAIN; C-REACTIVE PROTEIN; CYTOKINES; FEMALE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; LINEAR MODELS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; OSTEOPROTEGERIN; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; VON WILLEBRAND FACTOR; YOUNG ADULT;

EID: 84921481292     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2014.11.006     Document Type: Article

References (62)

1. Agartz I., Brown A.A., Rimol L.M., Hartberg C.B., Dale A.M., Melle I., Djurovic S., Andreassen O.A. Common sequence variants in the major histocompatibility complex region associate with cerebral ventricular size in schizophrenia. Biol. Psychiatry 2011, 70:696-698.
2. Arnone D., Cavanagh J., Gerber D., Lawrie S.M., Ebmeier K.P., McIntosh A.M. Magnetic resonance imaging studies in bipolar disorder and schizophrenia: meta-analysis. Br. J. Psychiatry 2009, 195:194-201.
3. Banks W.A., Kastin A.J., Broadwell R.D. Passage of cytokines across the blood-brain barrier. Neuroimmunomodulation 1995, 2:241-248.
4. Banks W.A., Farr S.A., Morley J.E. Entry of blood-borne cytokines into the central nervous system: effects on cognitive processes. Neuroimmunomodulation 2002, 10:319-327.
5. Bergink V., Gibney S.M., Drexhage H.A. Autoimmunity, inflammation, and psychosis: a search for peripheral markers. Biol. Psychiatry 2014, 75:324-331.
6. Berk M., Kapczinski F., Andreazza A.C., Dean O.M., Giorlando F., Maes M., Yucel M., Gama C.S., Dodd S., Dean B., Magalhaes P.V., Amminger P., McGorry P., Malhi G.S. Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors. Neurosci. Biobehav. Rev. 2011, 35:804-817.
7. Brown A.S., Derkits E.J. Prenatal infection and schizophrenia: a review of epidemiologic and translational studies. Am. J. Psychiatry 2010, 167:261-280.
8. Brown R.E., Stevens D.R., Haas H.L. The physiology of brain histamine. Prog. Neurobiol. 2001, 63:637-672.
9. Brydon L., Harrison N.A., Walker C., Steptoe A., Critchley H.D. Peripheral inflammation is associated with altered substantia nigra activity and psychomotor slowing in humans. Biol. Psychiatry 2008, 63:1022-1029.
10. Capuron L., Miller A.H. Immune system to brain signaling: neuropsychopharmacological implications. Pharmacol. Ther. 2011, 130:226-238.
11. Carlsson M., Carlsson A. Interactions between glutamatergic and monoaminergic systems within the basal ganglia-implications for schizophrenia and Parkinson's disease. Trends Neurosci. 1990, 13:272-276.
12. Carlsson M., Carlsson A. Schizophrenia: a subcortical neurotransmitter imbalance syndrome?. Schizophr. Bull. 1990, 16:425-432.
13. Carlsson A., Waters N., Carlsson M.L. Neurotransmitter interactions in schizophrenia-therapeutic implications. Biol. Psychiatry 1999, 46:1388-1395.
14. Chakos M.H., Shirakawa O., Lieberman J., Lee H., Bilder R., Tamminga C.A. Striatal enlargement in rats chronically treated with neuroleptic. Biol. Psychiatry 1998, 44:675-684.
15. Corson P.W., Nopoulos P., Miller D.D., Arndt S., Andreasen N.C. Change in basal ganglia volume over 2years in patients with schizophrenia: typical versus atypical neuroleptics. Am. J. Psychiatry 1999, 156:1200-1204.
16. Dale A.M., Fischl B., Sereno M.I. Cortical surface-based analysis. I. Segmentation and surface reconstruction. Neuroimage 1999, 9:179-194.
17. Dalman C., Allebeck P., Gunnell D., Harrison G., Kristensson K., Lewis G., Lofving S., Rasmussen F., Wicks S., Karlsson H. Infections in the CNS during childhood and the risk of subsequent psychotic illness: a cohort study of more than one million Swedish subjects. Am. J. Psychiatry 2008, 165:59-65.
18. Dickerson F., Stallings C., Origoni A., Boronow J., Yolken R. C-reactive protein is associated with the severity of cognitive impairment but not of psychiatric symptoms in individuals with schizophrenia. Schizophr. Res. 2007, 93:261-265.
19. Dickerson F., Stallings C., Origoni A., Vaughan C., Khushalani S., Yolken R. Elevated C-reactive protein and cognitive deficits in individuals with bipolar disorder. J. Affect. Disord. 2013, 150:456-459.
20. Dieset I., Djurovic S., Tesli M., Hope S., Mattingsdal M., Michelsen A., Joa I., Larsen T.K., Agartz I., Melle I., Rossberg J.I., Aukrust P., Andreassen O.A., Ueland T. Up-regulation of NOTCH4 gene expression in bipolar disorder. Am. J. Psychiatry 2012, 169:1292-1300.
21. Dieset I., Hope S., Ueland T., Bjella T., Agartz I., Melle I., Aukrust P., Rossberg J.I., Andreassen O.A. Cardiovascular risk factors during second generation antipsychotic treatment are associated with increased C-reactive protein. Schizophr. Res. 2012, 140:169-174.
22. Early T.S., Reiman E.M., Raichle M.E., Spitznagel E.L. Left globus pallidus abnormality in never-medicated patients with schizophrenia. Proc. Natl. Acad. Sci. U. S. A. 1987, 84:561-563.
23. Ebdrup B.H., Norbak H., Borgwardt S., Glenthoj B. Volumetric changes in the basal ganglia after antipsychotic monotherapy: a systematic review. Curr. Med. Chem. 2013, 20:438-447.
24. Eisenberger N.I., Berkman E.T., Inagaki T.K., Rameson L.T., Mashal N.M., Irwin M.R. Inflammation-induced anhedonia: endotoxin reduces ventral striatum responses to reward. Biol. Psychiatry 2010, 68:748-754.
25. Ellison-Wright I., Bullmore E. Anatomy of bipolar disorder and schizophrenia: a meta-analysis. Schizophr. Res. 2010, 117:1-12.
26. Ellison-Wright I., Glahn D.C., Laird A.R., Thelen S.M., Bullmore E. The anatomy of first-episode and chronic schizophrenia: an anatomical likelihood estimation meta-analysis. Am. J. Psychiatry 2008, 165:1015-1023.
27. Farde L., Wiesel F.A., Halldin C., Sedvall G. Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. Arch. Gen. Psychiatry 1988, 45:71-76.
28. Fillman S.G., Cloonan N., Catts V.S., Miller L.C., Wong J., McCrossin T., Cairns M., Weickert C.S. Increased inflammatory markers identified in the dorsolateral prefrontal cortex of individuals with schizophrenia. Mol. Psychiatry 2013, 18:206-214.
29. Fischl B., Dale A.M. Measuring the thickness of the human cerebral cortex from magnetic resonance images. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:11050-11055.
30. Fischl B., Sereno M.I., Dale A.M. Cortical surface-based analysis. II: inflation, flattening, and a surface-based coordinate system. Neuroimage 1999, 9:195-207.
31. Fischl B., Salat D.H., Busa E., Albert M., Dieterich M., Haselgrove C., van der Kouwe A., Killiany R., Kennedy D., Klaveness S., Montillo A., Makris N., Rosen B., Dale A.M. Whole brain segmentation: automated labeling of neuroanatomical structures in the human brain. Neuron 2002, 33:341-355.
32. Goldstein B.I., Kemp D.E., Soczynska J.K., McIntyre R.S. Inflammation and the phenomenology, pathophysiology, comorbidity, and treatment of bipolar disorder: a systematic review of the literature. J. Clin. Psychiatry 2009, 70:1078-1090.
33. Graybiel A.M. The basal ganglia: learning new tricks and loving it. Curr. Opin. Neurobiol. 2005, 15:638-644.
34. Graybiel A.M., Aosaki T., Flaherty A.W., Kimura M. The basal ganglia and adaptive motor control. Science 1994, 265:1826-1831.
35. Haroon E., Raison C.L., Miller A.H. Psychoneuroimmunology meets neuropsychopharmacology: translational implications of the impact of inflammation on behavior. Neuropsychopharmacology 2012, 37:137-162.
36. Harris L.W., Pietsch S., Cheng T.M., Schwarz E., Guest P.C., Bahn S. Comparison of peripheral and central schizophrenia biomarker profiles. PLoS ONE 2012, 7:e46368.
37. Hegde A.N., Mohan S., Lath N., Lim C.C. Differential diagnosis for bilateral abnormalities of the basal ganglia and thalamus. Radiographics 2011, 31:5-30.
38. Heringa S.M., van den Berg E., Reijmer Y.D., Nijpels G., Stehouwer C.D., Schalkwijk C.G., Teerlink T., Scheffer P.G., van den Hurk K., Kappelle L.J., Dekker J.M., Biessels G.J. Markers of low-grade inflammation and endothelial dysfunction are related to reduced information processing speed and executive functioning in an older population - the Hoorn Study. Psychoneuroendocrinology 2014, 40:108-118.
39. Ho B.C., Andreasen N.C., Ziebell S., Pierson R., Magnotta V. Long-term antipsychotic treatment and brain volumes: a longitudinal study of first-episode schizophrenia. Arch. Gen. Psychiatry 2011, 68:128-137.
40. Hope S., Melle I., Aukrust P., Steen N.E., Birkenaes A.B., Lorentzen S., Agartz I., Ueland T., Andreassen O.A. Similar immune profile in bipolar disorder and schizophrenia: selective increase in soluble tumor necrosis factor receptor I and von Willebrand factor. Bipolar Disord. 2009, 11:726-734.
41. Hope S., Melle I., Aukrust P., Agartz I., Lorentzen S., Steen N.E., Djurovic S., Ueland T., Andreassen O.A. Osteoprotegerin levels in patients with severe mental disorders. J. Psychiatry Neurosci. 2010, 35:304-310.
42. Ioannidis J.P. Excess significance bias in the literature on brain volume abnormalities. Arch. Gen. Psychiatry 2011, 68:773-780.
43. Jefferson A.L., Massaro J.M., Wolf P.A., Seshadri S., Au R., Vasan R.S., Larson M.G., Meigs J.B., Keaney J.F., Lipinska I., Kathiresan S., Benjamin E.J., DeCarli C. Inflammatory biomarkers are associated with total brain volume: the Framingham Heart Study. Neurology 2007, 68:1032-1038.
44. Kapur S. Psychosis as a state of aberrant salience: a framework linking biology, phenomenology, and pharmacology in schizophrenia. Am. J. Psychiatry 2003, 160:13-23.
45. Kirkpatrick B. Schizophrenia as a systemic disease. Schizophr. Bull. 2009, 35:381-382.
46. Leonard B.E. Is there an immunologic basis for schizophrenia?. Expert. Rev. Clin. Immunol. 2005, 1:103-112.
47. Lieberman J.A., Tollefson G.D., Charles C., Zipursky R., Sharma T., Kahn R.S., Keefe R.S., Green A.I., Gur R.E., McEvoy J., Perkins D., Hamer R.M., Gu H., Tohen M. Antipsychotic drug effects on brain morphology in first-episode psychosis. Arch. Gen. Psychiatry 2005, 62:361-370.
48. Lotrich F.E., Butters M.A., Aizenstein H., Marron M.M., Reynolds C.F., Gildengers A.G. The relationship between interleukin-1 receptor antagonist and cognitive function in older adults with bipolar disorder. Int. J. Geriatr. Psychiatry 2014, 29:635-644.
49. McAllister A.K. Major histocompatibility complex I in brain development and schizophrenia. Biol. Psychiatry 2014, 75:262-268.
50. Navari S., Dazzan P. Do antipsychotic drugs affect brain structure? A systematic and critical review of MRI findings. Psychol. Med. 2009, 39:1763-1777.
51. Packard M.G., Knowlton B.J. Learning and memory functions of the basal ganglia. Annu. Rev. Neurosci. 2002, 25:563-593.
52. Paulus P., Jennewein C., Zacharowski K. Biomarkers of endothelial dysfunction: can they help us deciphering systemic inflammation and sepsis?. Biomarkers 2011, 16(Suppl. 1):S11-S21.
53. Perez-Costas E., Melendez-Ferro M., Roberts R.C. Basal ganglia pathology in schizophrenia: dopamine connections and anomalies. J. Neurochem. 2010, 113:287-302.
54. Potvin S., Stip E., Sepehry A.A., Gendron A., Bah R., Kouassi E. Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review. Biol. Psychiatry 2008, 63:801-808.
55. Quinn T.J., Gallacher J., Deary I.J., Lowe G.D., Fenton C., Stott D.J. Association between circulating hemostatic measures and dementia or cognitive impairment: systematic review and meta-analyzes. J. Thromb. Haemost. 2011, 9:1475-1482.
56. Rimol L.M., Hartberg C.B., Nesvag R., Fennema-Notestine C., Hagler D.J., Pung C.J., Jennings R.G., Haukvik U.K., Lange E., Nakstad P.H., Melle I., Andreassen O.A., Dale A.M., Agartz I. Cortical thickness and subcortical volumes in schizophrenia and bipolar disorder. Biol. Psychiatry 2010, 68:41-50.
57. Rimol L.M., Nesvag R., Hagler D.J., Bergmann O., Fennema-Notestine C., Hartberg C.B., Haukvik U.K., Lange E., Pung C.J., Server A., Melle I., Andreassen O.A., Agartz I., Dale A.M. Cortical volume, surface area, and thickness in schizophrenia and bipolar disorder. Biol. Psychiatry 2012, 71:552-560.
58. Ripke S., Sanders A.R., Kendler K.S., Levinson D.F., Sklar P., Holmans P.A. Genome-wide association study identifies five new schizophrenia loci. Nat. Genet. 2011, 43:969-976.
59. Shepherd A.M., Laurens K.R., Matheson S.L., Carr V.J., Green M.J. Systematic meta-review and quality assessment of the structural brain alterations in schizophrenia. Neurosci. Biobehav. Rev. 2012, 36:1342-1356.
60. Stefansson H., Ophoff R.A., Steinberg S., Andreassen O.A., Cichon S., Rujescu D., Werge T., Pietilainen O.P., Mors O., Mortensen P.B., Sigurdsson E., Gustafsson O., Nyegaard M., Tuulio-Henriksson A., Ingason A., Hansen T., Suvisaari J., Lonnqvist J., Paunio T., Borglum A.D., Hartmann A., Fink-Jensen A., Nordentoft M., Hougaard D., Norgaard-Pedersen B., Bottcher Y., Olesen J., Breuer R., Moller H.J., Giegling I., Rasmussen H.B., Timm S., Mattheisen M., Bitter I., Rethelyi J.M., Magnusdottir B.B., Sigmundsson T., Olason P., Masson G., Gulcher J.R., Haraldsson M., Fossdal R., Thorgeirsson T.E., Thorsteinsdottir U., Ruggeri M., Tosato S., Franke B., Strengman E., Kiemeney L.A., Melle I., Djurovic S., Abramova L., Kaleda V., Sanjuan J., de, F.R., Bramon E., Vassos E., Fraser G., Ettinger U., Picchioni M., Walker N., Toulopoulou T., Need A.C., Ge D., Yoon J.L., Shianna K.V., Freimer N.B., Cantor R.M., Murray R., Kong A., Golimbet V., Carracedo A., Arango C., Costas J., Jonsson E.G., Terenius L., Agartz I., Petursson H., Nothen M.M., Rietschel M., Matthews P.M., Muglia P., Peltonen L., St C.D., Goldstein D.B., Stefansson K., Collier D.A. Common variants conferring risk of schizophrenia. Nature 2009, 460:744-747.
61. Westin J.E., Lindgren H.S., Gardi J., Nyengaard J.R., Brundin P., Mohapel P., Cenci M.A. Endothelial proliferation and increased blood-brain barrier permeability in the basal ganglia in a rat model of 3,4-dihydroxyphenyl-l-alanine-induced dyskinesia. J. Neurosci. 2006, 26:9448-9461.
62. Wraith D.C., Nicholson L.B. The adaptive immune system in diseases of the central nervous system. J. Clin. Invest. 2012, 122:1172-1179.